The efficient, well-coordinated distribution, allocation, and mass vaccination activities against the
novel coronavirus (SARS-CoV-2) will help ensure vaccination is an effective countermeasure to the current pandemic.

On Oct. 5, AMCP submitted comments about the Part D MTM program, specifically in regards to the ability of plan sponsors and MTM vendors to provide annual CMR to individuals other than the beneficiary in certain circumstances in which the beneficiary is unable to participate.

On September 25, FDA issued a final rule related to the importation of prescription drugs from Canada.

Read AMCP's summary of the Medicare Coverage of Innovative Technology proposed rule that would provide a national coverage pathway for breakthrough devices, including digital therapeutics.

AMCP submitted comments in response to a request for information on how to improve the FDA Orange Book.

AMCP submitted comments to the National Academies of Science, Engineering, and Medicine’s draft Preliminary Framework for COVID-19 Vaccine detailing our support to recognize pharmacists as front-line health care workers and pharmacies be included in the vaccine distribution and allocation plans.

AMCP signed on to joint comments on the National Academies of Science, Engineering, and Medicine’s draft Preliminary Framework for COVID-19 Vaccine, advocating for the inclusion of pharmacists as front line health care workers.